HC Wainwright increases earnings estimates for ImmunityBio. August 5, 2026 Key points. * HC Wainwright raised its FY2027 EPS estimate for ImmunityBio to $0.07 from $0.06 and maintained a Buy rating with a $15 price target. * Analyst sentiment is generally positive, with six Buy ratings and one Sell rating, resulting in a Moderate Buy consensus and an average price target of $14.20. * ImmunityBio reported a quarterly loss of $0.22 per share, missing expectations by $0.14, though revenue of $51.24 million exceeded estimates. Shares opened at $6.95, while insiders have sold about $3.9 million of stock over the past 90 days. * Five stocks to consider instead of ImmunityBio. ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) - Equities researchers at HC Wainwright increased their FY2027 earnings per share estimates for shares of ImmunityBio in a report released on Tuesday, August 4th. HC Wainwright analyst A. Maldonado now expects that the company will earn $0.07 per share for the year, up from their previous forecast of $0.06. HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for ImmunityBio's current full-year earnings is ($0.31) per share. Several other equities analysts also recently issued reports on IBRX. BTIG Research reaffirmed a "buy" rating and set a $12.00 price objective on shares of ImmunityBio in a report on Thursday, May 21st. Weiss Ratings reissued a "sell (d-)" rating on shares of ImmunityBio in a research note on Friday, July 10th. Finally, D. Boral Capital restated a "buy" rating and set a $23.00 price target on shares of ImmunityBio in a research report on Tuesday, May 5th. Six research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $14.20. ImmunityBio stock performance. Shares of NASDAQ IBRX opened at $6.95 on Wednesday. The firm has a fifty day moving average of $7.68 and a 200 day moving average of $7.62. The firm has a market cap of $7.28 billion, a PE ratio of -8.18 and a beta of 0.03. ImmunityBio has a one year low of $1.95 and a one year high of $12.43. ImmunityBio (NASDAQ:IBRX - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million during the quarter, compared to analysts' expectations of $49.80 million. Institutional investors weigh in on ImmunityBio. Large investors have recently modified their holdings of the business. WealthPlan Investment Management LLC purchased a new position in shares of ImmunityBio in the fourth quarter worth about $27,000. Diversify Advisory Services LLC purchased a new stake in ImmunityBio during the 2nd quarter valued at about $27,000. Kovack Advisors Inc. acquired a new stake in ImmunityBio in the 4th quarter valued at about $27,000. Opal Wealth Advisors LLC acquired a new stake in ImmunityBio in the 4th quarter valued at about $28,000. Finally, Empowered Funds LLC purchased a new position in ImmunityBio in the 4th quarter worth approximately $28,000. Hedge funds and other institutional investors own 8.58% of the company's stock. Insider transactions at ImmunityBio. In related news, Director Christobel Selecky sold 159,478 shares of the business's stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $9.02, for a total transaction of $1,438,491.56. Following the completion of the sale, the director directly owned 35,064 shares in the company, valued at approximately $316,277.28. The trade was a 81.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total value of $197,000.00. Following the completion of the transaction, the director directly owned 2,802,788 shares of the company's stock, valued at approximately $22,085,969.44. This represents a 0.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,443 shares of company stock valued at $3,918,819 over the last ninety days. Insiders own 66.10% of the company's stock. About ImmunityBio. ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company's research platform centers on harnessing the power of the human immune system - through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines - to target and eliminate diseased cells across a range of indications. Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider ImmunityBio, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list. While ImmunityBio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

ImmunityBio's stock surged 9% on 30 July after UAE regulators approved its cancer drug ANKTIVA for bladder cancer and advanced non-small cell lung cancer, bringing approvals to 34 countries. However, shares gave back gains, falling 4% by 31 July and slipping further on Monday. The company is set to report second-quarter results in mid-August. Wall Street expects revenue of $49.2 million and a loss of $0.09 per share, following strong first-quarter product sales of $44.2 million, up 168% year-over-year. ImmunityBio plans to seek expanded FDA approval for ANKTIVA in bladder cancer patients later in 2026, with another FDA decision expected in early 2027.

UAE approves ANKTIVA for bladder cancer and advanced lung cancer. UAE approves ANKTIVA for BCG-unresponsive NMIBC and metastatic NSCLC after checkpoint inhibitor failure, expanding its regulatory footprint to 34 countries. The Emirates Drug Establishment (EDE) has granted Marketing Authorization for two presentations of ANKTIVA(R)(nogapendekin alfa inbakicept), expanding the immunotherapy's approved use to adults with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) and metastatic non-small cell lung cancer (NSCLC) that has progressed after checkpoint inhibitor-based treatment. The authorization marks the broadest regulatory approval for ANKTIVA to date and extends its global regulatory footprint to 34 countries. The UAE becomes the first regulatory jurisdiction to approve ANKTIVA across the full spectrum of BCG-unresponsive NMIBC, including carcinoma in situ (CIS) with or without papillary tumors as well as papillary disease alone, a patient population with limited bladder-preserving treatment options. Mechanism of action: target innate & adaptive immunity. ANKTIVA is a first-in-class IL-15 receptor agonist IgG1 fusion complex that activates natural killer (NK) cells, CD8-positive cytotoxic T cells, and memory T cells. By stimulating both innate and adaptive immune responses, the therapy aims to restore anti-tumor immunity, particularly in cancers that evade conventional T-cell-mediated immune surveillance. Patients with BCG-unresponsive NMIBC often face radical cystectomy after failure of intravesical Bacillus Calmette-Guérin (BCG) therapy. Similarly, therapeutic options remain limited for metastatic NSCLC following progression on immune checkpoint inhibitors and chemotherapy. Clinical trial foundations. NMIBC cohorts: registrational Phase 2/3 QUILT-3.032 study. The NMIBC authorization is supported by the registrational Phase 2/3 QUILT-3.032 study (NCT03022825). Among 100 patients with CIS with or without papillary tumors, ANKTIVA combined with BCG achieved a 71% complete response rate (95% CI: 61-80). Responses remained durable, with complete response durations extending beyond 54 months. At 12 months, 66% of responders maintained complete response, while 42% remained in complete response at 24 months. In the papillary-only cohort (n=80), the combination produced a 58.2% disease-free survival rate at 12 months (95% CI: 46.6-68.2), a median disease-free survival of 25.3 months, and an 83.1% cystectomy-free rate at 36 months. Treatment was generally well tolerated. Most treatment-related adverse events were Grade 1 or 2, Grade 3 events occurred in only 1% of patients, and no Grade 4 or Grade 5 treatment-related adverse events were reported. Advanced NSCLC Cohort: Phase 2 QUILT-3.055 Study The NSCLC approval is supported by the Phase 2 QUILT-3.055 study (NCT03228667), which evaluated ANKTIVA plus a checkpoint inhibitor in 79 patients with checkpoint-refractory advanced NSCLC. The regimen achieved a median overall survival of 14.6 months (95% CI: 12.0-19.5). Patients who reached an on-treatment absolute lymphocyte count of at least 1,000 cells/μL experienced a longer median overall survival of 16.2 months compared with 11.8 months among those with lower lymphocyte counts. Common treatment-related adverse events included injection-site reactions, chills, fatigue, pyrexia, nausea, and influenza-like illness. Leadership highlights broader clinical impact. ImmunityBio said the UAE approval reflects the growing clinical evidence supporting IL-15-based immunotherapy across multiple tumor types. Company leadership highlighted the significance of expanding bladder-preserving treatment options for patients with BCG-unresponsive NMIBC while extending the same immune activation strategy to metastatic NSCLC after checkpoint inhibitor failure. The company also noted that both UAE approvals were supported by clinical data packages previously submitted to the U.S. Food and Drug Administration. The UAE authorization is valid through July 2031 and covers ANKTIVA 0.4 mg/0.4 mL for intravesical use with BCG in NMIBC and ANKTIVA 1.2 mg/0.6 mL for subcutaneous administration with immune checkpoint inhibitors in metastatic NSCLC. ImmunityBio plans to expand patient access across the Gulf region through its partnership with Modern Pharmaceutical Company, building on approvals already secured in the United States, United Kingdom, Saudi Arabia, the European Union, and now the United Arab Emirates. Reference. About the writer. Nalam Karthik (LinkedIn) is a healthcare writer and PharmD graduate with interests in pharmacovigilance, drug safety, clinical data analysis, and quality assurance. He is passionate about translating clinical and pharmaceutical knowledge into accessible healthcare content while staying engaged with advancements in drug development and patient safety initiatives.